According to Guhan Pharmaceutical's announcement, as of the announcement disclosure date, Shanghai Xilexian, the controlling shareholder, has increased its holdings of the company by 4.9502 million shares through centralized bidding transactions, accounting for 2.07% of the total share capital. After this equity change, Hunan Celesian and its co-actors held a total of 64.6572 million shares, accounting for 27.00% of the total share capital. The change hit an integer multiple of 1%. Shanghai Celestine plans to increase its holdings by no less than 20 million yuan within 6 months. Currently, the plan to increase its holdings has not been completed, and there is a risk of uncertainty about implementation.

According to Guhan Pharmaceutical's announcement, as of the announcement disclosure date, Shanghai Xilexian, the controlling shareholder, has increased its holdings of the company by 4.9502 million shares through centralized bidding transactions, accounting for 2.07% of the total share capital. After this equity change, Hunan Celesian and its co-actors held a total of 64.6572 million shares, accounting for 27.00% of the total share capital. The change hit an integer multiple of 1%. Shanghai Celestine plans to increase its holdings by no less than 20 million yuan within 6 months. Currently, the plan to increase its holdings has not been completed, and there is a risk of uncertainty about implementation.